#United States #Investor Relations #IDEAYA Biosciences #South San Francisco #Precision Medicine

IDEAYA Biosciences Declares Participation in November 2026 Investor Relations Events

IDEAYA Biosciences, Inc., a company focused on precision medicine in oncology, recently announced its active role in a series of investor relations events scheduled for November 2026. This move aims to enhance transparency and foster engagement with investors while unveiling groundbreaking advancements in the fight against cancer.

Event Overview

On November 16, 2026, IDEAYA will kick off its participation at the UBS Global Biopharma Conference in London, where the company’s Chairman and CEO, Yujiro S. Hata, will engage in a fireside chat moderated by Michael Yee, a prominent figure in biotechnology research.

Following this, IDEAYA will host its Investor RD Day, providing insights into its promising drug candidate, IDE892, which is being developed as a potential leading therapeutic option for cancers driven by specific genetic alterations. Attendees can expect to hear about the promising early clinical data from IDE892, which targets methylthioadenosine phosphorylase (MTAP) cooperative PRMT5 inhibition and its implications in addressing malignancies such as pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC).

Additionally, IDEAYA plans to share progress related to its research on various forms of RAS mutations. The company aims to present compelling preclinical data that supports its comprehensive strategies targeting genetic anomalies, as well as clinical combination tactics utilizing IDE892 and other candidates in their pipeline.

Notable Highlights

During the Investor RD Day, IDEAYA's Chief Financial Officer, Joshua Bleharski, alongside other corporate leaders, will explore the emerging data and forthcoming challenges in the therapeutic landscape. They will also discuss the regulatory milestones expected in 2027 that could enhance the drug candidates' marketability and availability to patients.

The engagement will feature insights from Dr. Frank McCormick, a highly respected oncologist from the UCSF Helen Diller Family Comprehensive Cancer Center, further bolstering the credence of IDEAYA's pivotal findings.

On the following day, November 17, IDEAYA will feature in the Jefferies Global Healthcare Conference, continuing the momentum established in the prior events. The format will remain consistent with a fireside chat featuring the executive leadership team discussing the company’s strategies and financial outlook.

How to Participate

For those interested in learning more about IDEAYA’s advancements, registration for both in-person and virtual attendance at these events is mandatory. Interested investors and stakeholders can register through the designated events platform for their respective sessions. Furthermore, live audio webcasts of these discussions will be accessible via the IDEAYA website following the events, allowing for wider reach and inclusivity.

About IDEAYA Biosciences

IDEAYA Biosciences is at the forefront of precision medicine, tailoring innovative therapies for cancer treatment aligned with specific genetic profiles. The company blends sophisticated drug discovery processes with robust bioinformatics to advance its mission of introducing novel oncology treatments. Their commitment to addressing genetic drivers of diseases compels IDEAYA to develop personalized and effective therapeutic ventures for patients combatting various forms of cancer.

As IDEAYA prepares for these significant investor events, stakeholders should anticipate a wealth of information on groundbreaking cancer therapies and the company’s trajectory towards clinical advancements. This active engagement serves as another benchmark of IDEAYA's dedication to enhancing the landscape of oncology medicine, potentially altering patient outcomes and advancing the fight against cancer.